C4 Therapeutics, Inc. CCCC

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18
Revenue	35.95	35.58	20.76	31.10	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Revenue Growth	1.02%	71.44%	(33.25%)	(32.08%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Cost of Revenue	—	—	—	7.57	‡‡‡‡‡	—	—	—
Gross Profit	35.95	35.58	20.76	31.10	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
R&D Expenses	104.24	110.64	117.71	117.84	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
SG&A Expenses	36.20	42.12	42.08	42.79	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating Income	(115.22)	(119.61)	(139.03)	(129.53)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Interest Expense (Operating)	—	—	—	2.22	‡‡‡‡‡	‡‡‡‡‡	—	—
Non-operating Income/Expense	10.35	14.43	7.82	1.36	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Non-operating Interest Expenses	(10.35)	(14.43)	1.37	2.22	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBT	(104.87)	(105.18)	(131.21)	(128.17)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Income Tax Provision	0.12	0.13	1.28	—	—	‡‡‡‡‡	‡‡‡‡‡	—
Income after Tax	(104.99)	(105.32)	(132.49)	(128.17)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Dividends (Preferred)	—	0.00	—	—	‡‡‡	—	‡‡‡‡‡	—
Net Income Common	(104.99)	(105.32)	(132.49)	(128.17)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Basic)	(1.27)	(1.52)	(2.67)	(2.62)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Diluted)	(1.27)	(1.52)	(2.67)	(2.62)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Shares (Basic, Weighted)	82.89	69.37	49.64	48.86	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Shares (Diluted, Weighted)	82.89	69.37	49.64	48.86	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Gross Margin	100.00%	100.00%	100.00%	100.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡
EBIT Margin	(320.53%)	(336.15%)	(669.84%)	(416.56%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBT margin	(291.74%)	(295.60%)	(632.17%)	(412.19%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Profit Margin	(292.08%)	(295.96%)	(638.34%)	(412.19%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow Margin	(276.24%)	(183.61%)	(522.96%)	(358.36%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBITDA	(116.00)	(123.19)	(140.53)	(126.43)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBIT	(115.22)	(119.61)	(139.03)	(129.53)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Income from Continuous Operations	(104.99)	(105.32)	(132.49)	(128.17)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Consolidated Net Income/Loss	(104.99)	(105.32)	(132.49)	(128.17)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Basic, from Continuous Ops)	(1.27)	(1.52)	(2.67)	(2.62)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
EPS (Basic, Consolidated)	(1.27)	(1.52)	(2.67)	(2.62)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
EPS (Diluted, from Cont. Ops)	(1.27)	(1.52)	(2.67)	(2.62)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Shares (Diluted, Average)	82.90	69.37	49.64	48.86	‡‡‡‡‡	‡‡‡‡‡	—	—
EPS (Diluted, Consolidated)	(1.27)	(1.52)	(2.67)	(2.62)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
EBITDA Margin	(322.71%)	(346.20%)	(677.06%)	(406.58%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating Cash Flow Margin	(274.55%)	(183.11%)	(514.73%)	(340.68%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now